Evidence map›Paper›PMID 41615147›Full record

ArticleHuman vaccines & immunotherapeutics2026

Pentameric M2e influenza vaccine candidate generates strong immunity with limited survival benefit.

Varun Kumar, Preeti Vishwakarma, Sneha Raj, Shikha Saxena, Zaigham Abbas Rizvi, Amit Kumar, Amit Awasthi, Sweety Samal

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Varun KumarCentre for Virus Research, Therapeutics and Vaccines, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Preeti VishwakarmaCentre for Virus Research, Therapeutics and Vaccines, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Sneha RajCentre for Virus Research, Therapeutics and Vaccines, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Shikha SaxenaCentre for Virus Research, Therapeutics and Vaccines, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Zaigham Abbas RizviCentre for Virus Research, Therapeutics and Vaccines, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Amit KumarCentre for Virus Research, Therapeutics and Vaccines, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Amit AwasthiImmunobiology and Immunology Core Laboratory, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Sweety SamalCentre for Virus Research, Therapeutics and Vaccines, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously demonstrated that native-like oligomers of Influenza A H1N1 M2e, expressed in Expi293F cells, elicit robust immune responses. Building on this foundation, we engineered a recombinant antigen comprising five tandem repeats of the M2e epitope (M2e-5x) fused to the tGCN4 domain, which promotes oligomerization and stability. BALB/c mice were immunized intramuscularly with M2e-5x antigen formulated in AddaVax

Indexed as

Influenza VaccinesOrthomyxoviridae InfectionsViral Matrix ProteinsAnimalsAntibodies, ViralDisease Models, AnimalEpitopesFemaleImmunization, SecondaryInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInjections, IntramuscularLungMiceMice, Inbred BALB CProtein Subunit VaccinesAntibodies, ViralEpitopesInfluenza VaccinesM2 protein, Influenza A virusProtein Subunit VaccinesVaccines, SyntheticViral Matrix ProteinsViroporin Proteinsimmunogenicityinfluenza virusM2e proteinprotectionvaccine

Identifiers

PMID41615147
PMCPMC12867357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.